The endolysosomal pathway and ALS/FTD

Trends Neurosci. 2023 Dec;46(12):1025-1041. doi: 10.1016/j.tins.2023.09.004. Epub 2023 Oct 10.

Abstract

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are considered to be part of a disease spectrum that is associated with causative mutations and risk variants in a wide range of genes. Mounting evidence indicates that several of these genes are linked to the endolysosomal system, highlighting the importance of this pathway in ALS/FTD. Although many studies have focused on how disruption of this pathway impacts on autophagy, recent findings reveal that this may not be the whole picture: specifically, disrupting autophagy may not be sufficient to induce disease, whereas disrupting the endolysosomal system could represent a crucial pathogenic driver. In this review we discuss the connections between ALS/FTD and the endolysosomal system, including a breakdown of how disease-associated genes are implicated in this pathway. We also explore the potential downstream consequences of disrupting endolysosomal activity in the brain, outside of an effect on autophagy.

Keywords: C9ORF72; TDP-43; TMEM106B; autophagy; neurodegeneration; proteinopathy.

Publication types

  • Review

MeSH terms

  • Amyotrophic Lateral Sclerosis* / genetics
  • Amyotrophic Lateral Sclerosis* / metabolism
  • Autophagy
  • C9orf72 Protein / genetics
  • Frontotemporal Dementia* / genetics
  • Humans
  • Mutation

Substances

  • C9orf72 Protein